Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | MERTK | Q12866 | 11/20 | 0.50 |
| ▸ | AXL | P30530 | 8/20 | 0.50 |
| ▸ | TACR1 | P25103 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534809 | 0.97 | MERTK (0.53) | KCNA5MERTKAXLTACR1MET | |
| SCHEMBL27701237 | 0.89 | KCNA5 (0.53) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL12629181 | 0.83 | P2RX7 (0.52) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL13324324 | 0.83 | P2RX7 (0.52) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL4075331 | 0.81 | P2RX7 (0.50) | KCNA5MERTKAXLMETTYRO3 | |
| SCHEMBL4380010 | 0.81 | KMT2A (0.51) | KCNA5MERTKAXLTACR1MET | |
| SCHEMBL1928743 | 0.81 | KMT2A (0.51) | KCNA5MERTKAXLTACR1MET | |
| SCHEMBL14583914 | 0.81 | KMT2A (0.51) | KCNA5MERTKAXLTACR1MET | |
| SCHEMBL8280167 | 0.81 | KMT2A (0.51) | KCNA5MERTKAXLTACR1MET | |
| SCHEMBL13302610 | 0.80 | MERTK (0.49) | KCNA5MERTKAXLMETTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | KCNA5 801/4885MERTK 3910/4885AXL 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.